Meeting
2014 ASCO Annual Meeting
A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX (mFOLFIRINOX) in previously untreated patients (pts) with advanced gastrointestinal malignancies.
Authors
Manish Sharma
The University of Chicago Medicine, Chicago, IL
Manish Sharma , Daniel Virgil Thomas Catenacci , Theodore Karrison , Kenisha Allen , Jaclyn D Peterson , Robert de Wilton Marsh , Mark Kozloff , Blase N. Polite , Hedy Lee Kindler
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Clinical Trial Registration Number
NCT01643499
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 4125)
DOI
10.1200/jco.2014.32.15_suppl.4125
Abstract #
4125
Poster Bd #
212
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX (mFOLFIRINOX) in previously untreated patients (pts) with advanced gastrointestinal malignancies.
First Author: Manish Sharma
Poster
2018 Gastrointestinal Cancers Symposium
Safety and tolerability of 5-FU, irinotecan (IRI), and nab-paclitaxel (FOLFIRABRAX) with genotype-guided dosing of IRI in previously untreated patients with advanced gastrointestinal (GI) malignancies.
First Author: Smita Suhas Joshi
Poster
2017 Gastrointestinal Cancers Symposium
A single arm, prospective multicenter phase II study FOLFIRINOX in patients with advanced and recurrent biliary tract cancer.
First Author: Naminatsu Takahara
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A multicenter phase Ib/II study of liposomal-irinotecan, 5-fluorouracil (5-FU), and leucovorin (LV) with nivolumab as second-line therapy for patients with advanced biliary tract cancer (BilT-03).
First Author: Vaibhav Sahai